| Professional Services Industry | Industrials Sector | Kim Stratton CEO | XMUN Exchange | NL0014040206 ISIN |
| DE Country | 384 Employees | - Last Dividend | - Last Split | - IPO Date |
Centogene N.V., based in Rostock, Germany, with its global subsidiaries, stands at the forefront of pharmaceutical solutions and diagnostic testing across various regions including Europe, the Middle East, North America, Latin America, and the Asia Pacific. Since its founding in 2006, Centogene has revolutionized the approach towards understanding, diagnosing, and treating rare and neurodegenerative diseases. By leveraging its expertise in genomics and multiomics, together with its expansive biodata bank, Centogene delivers comprehensive, data-driven insights to patients, healthcare professionals, and pharmaceutical companies. Its initiatives are geared towards accelerating the path to diagnosis and treatment, thereby significantly impacting patient care in the domain of rare diseases and neurodegeneration.
A state-of-the-art, single-step multiomic solution that integrates DNA sequencing, biochemical testing, and RNA sequencing. This comprehensive approach aims to provide a holistic view of a patient's genetic makeup, thereby enabling more precise diagnostics and tailored treatment strategies.
A sophisticated cloud-based Software as a Service (SaaS) platform designed to streamline the analysis, interpretation, and reporting of genomic variants. CentoCloud facilitates laboratories worldwide in adopting advanced genetic testing capabilities, enhancing the efficiency and reach of rare disease diagnostics.
This web-based application simplifies the intricate process of genetic data interpretation. FilterTool empowers researchers and clinicians to navigate vast genomic datasets effectively, enabling them to identify relevant genetic variations with both precision and ease.
Centogene's Next Generation Sequencing (NGS)-based assay that sets new standards in diagnostic testing. NEW CentoGenome offers comprehensive diagnostic information, including the identification of rare genetic disorders, which is crucial in expediting access to potential treatment avenues.
Centogene extends its offerings beyond diagnostics to include target and drug screening, clinical development, and strategies for market access and expansion. Through CENTOGENE Biodatabank licenses and refined insight reports, it provides invaluable resources for drug discovery and development processes.
Centered around patient care, Centogene offers services that range from early patient recruitment and identification to epidemiological insights, biomarker discovery, and patient monitoring. It serves physicians, laboratories, and hospitals directly or through distributors, offering whole exome sequencing, whole genome sequencing, and multiomic testing solutions that are pivotal in rare disease diagnosis and management.